Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Knight Therapeutics Company Profile (CVE:GUD)

Consensus Ratings for Knight Therapeutics (CVE:GUD) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: C$6.50

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/20/2014LB SecuritiesInitiated CoverageHoldViewTweet This Rating  Share This Rating on StockTwits
8/28/2014NBFInitiated CoverageOutperformC$6.50ViewTweet This Rating  Share This Rating on StockTwits
8/28/2014National Bank FinancialInitiated CoverageOutperformC$6.50ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/24/2012 forward)